The ASCO Post
LightNews LightNews
banner
ascopost.bsky.social
The ASCO Post
@ascopost.bsky.social
1.4K followers 960 following 180 posts
News and views from the world of clinical oncology and hematology
Posts Replies Media Videos
ascopost.bsky.social
BART trial ASTRO25: Adjuvant Radiation Therapy after cystectomy reduced locoregional recurrence in pts w/ high-risk muscle-invasive Bladder Cancer Modern IMRT to the pelvis safe after surgery—supports IO integration in trials
🔷 Presenter Vedang Murthy, MD
🔗 https://ow.ly/Qexr50XrI7o
November 14, 2025 at 4:01 PM
ascopost.bsky.social
The NCCN's Clinical Practice Guidelines in Oncology to be integrated into @openevidence.bsky.social's medical AI platform so clinicians can access trusted, evidence-based cancer care recommendations for decision-making support via natural language search.

➡️https://ow.ly/QqaK50Xr3w4
November 13, 2025 at 6:15 PM
ascopost.bsky.social
Pembrolizumab + weekly paclitaxel ± bevacizumab in pts with platinum-resistant ovarian cancer led to improved PFS, OS in overall, PD-L1 CPS ≥ 1 populations ovariancancer
🗣️From ESMO25
👩‍⚕️Presenter Nicoletta Colombo, MD, PhD; Discussant
https://ow.ly/FgHC50XqFJc
November 12, 2025 at 8:01 PM
ascopost.bsky.social
The November 10 issue of The ASCO Post features insights from ESMO, ASTRO, and SOHO meetings; a Special Report on disaster impacts on patients & staff; perspectives on alcohol-associated cancer risks, and climate change & cancer development.

Read full issue here: ascopost.com/issues/novem...
November 11, 2025 at 6:15 PM
ascopost.bsky.social
Zenocutuzumab-zbco led to responses in 37% of patients in a small cohort of patients with NRG1+ cholangiocarcinoma
🔹Clinical benefit rate 58%, median PFS of 9.2 months
🔹Presented at #Targets25 by Alison Schram, MD of @mskcancercenter.bsky.social

ascopost.com/news/october...
November 10, 2025 at 4:52 PM
ascopost.bsky.social
A conversation with Ravi B. Parikh, MD, MPP, highlights how he has helped increase access to palliative care by integrating an algorithm into EHR to identify patients with cancer who could benefit

Palliative care visits increased: 44% vs 8% in control group

ascopost.com/issues/octob...
November 7, 2025 at 3:22 PM
ascopost.bsky.social
Living a Full Life: The ASCO Post spotlights the career of third-generation clinician Neelima Denduluri, MD, in conversation with @jameabraham.bsky.social. Dr. Denduluri has been a lifetime advocate for equity in medicine, breast cancer oncologist, ASCO mentor, & more.

ascopost.com/issues/octob...
November 6, 2025 at 6:05 PM
ascopost.bsky.social
“Cancer is probably the most vulnerable field for fraudulent research” -Reese A.K. Richardson, PhD, of @kelloggschoolnu.bsky.social

Richardson et al reported the amount of fraudulent scientific papers is doubling every 1.5 years due to paper mills, etc.

ascopost.com/news/october...
October 31, 2025 at 5:02 PM
ascopost.bsky.social
President Joe Biden has completed his radiation therapy course for prostate cancer and rang a ceremonial bell to commemorate the milestone

ascopost.com/news/october...
President Biden Completes Radiation Therapy Course
President Joe Biden has completed his course of radiation therapy for prostate cancer, which he recently marked by ringing the ceremonial bell alongside his radiation oncology care team.
ascopost.com
October 30, 2025 at 3:29 PM
ascopost.bsky.social
Obesity-related cancers on the rise in younger and older adults globally, with data from 42 countries

Incidence rates rose for 6 of 13 cancer types; rates of endometrial cancer and kidney cancer rose most sharply

From Amy Berrington de Gonzalez, DPhil @icr.ac.uk et al

ascopost.com/news/october...
October 29, 2025 at 6:27 PM
ascopost.bsky.social
Only 45% of US counties have oncologists and retirement looms for many

New data show number of US oncologists billing Medicare rose from 2014 to 2024, but oncologist density/100,000 adults decreased

Corresponding author M. Kelsey Kirkwood, MPH @ascocancer.bsky.social

ascopost.com/news/october...
October 28, 2025 at 4:01 PM
ascopost.bsky.social
FDA Approval: The @fda.gov has approved revumenib (Revuforj) for R/R acute myeloid leukemia with a susceptible NPM1 mutation in adult & pediatric patients ≥1yr without alternative treatment options

Supportive data from AUGMENT-101 trial show CR+CRh rate of 23.1%

ascopost.com/news/october...
October 27, 2025 at 3:49 PM
ascopost.bsky.social
When it comes to cancer survival, study by Tohmasi et al confirms ‘it’s never too late’ to quit smoking. 🚬

Benefits seen across all cancer types and stages, including late-stage cancer

Expert commentary from James M. Davis, MD, of @dukecancer.bsky.social

ascopost.com/news/october...
October 24, 2025 at 4:06 PM
ascopost.bsky.social
evERA study from ESMO 2025: Oral giredestrant + everolimus improved PFS vs SoC in metastatic ER+, HER2– breast cancer

Risk of disease progression or death reduced by 63% in ESR1-mutant cohort, 44% in ITT cohort

Presented by @elmayermd.bsky.social

ascopost.com/news/october...
October 23, 2025 at 3:22 PM
ascopost.bsky.social
Meta analysis by Alessandro Di Federico, MD, et al: Dual CTLA-4 + PD-1/PD-L1 blockade in NSCLC yielded 5-year OS of 19.8% vs 16.3% with monotherapy

Median OS was longer in patients with PD-L1 TPS <1% & STK11 mutations

Corresponding author: Biagio Ricciuti, MD, PhD

ascopost.com/news/october...
October 21, 2025 at 6:21 PM
ascopost.bsky.social
New study from @alliance-org.bsky.social and AML Cooperative Group asks: Are age-based treatment classifications outdated?
🔻 5yr OS by age: 73% (ages 18–24) to 21% (≥75)

@akeisfeld.bsky.social suggests a shift toward biology-driven eligibility over age thresholds.

ascopost.com/news/october...
October 20, 2025 at 3:34 PM
ascopost.bsky.social
In patients <50 undergoing colonoscopy, odds for early-onset colorectal cancer higher in those with rectal bleeding.

"If you have a person below the screening age with rectal bleeding, you should seriously consider a colonoscopy.” -
Sandra Kavalukas, MD, at #ACS25

ascopost.com/news/october...
October 17, 2025 at 6:40 PM
ascopost.bsky.social
FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women

Supports expansion of guidelines to include high-risk populations

Presenter: @elaineshummd.bsky.social
Discussant: David R. Baldwin, MD

ascopost.com/news/october...
October 16, 2025 at 5:21 PM
ascopost.bsky.social
A 313-SNP polygenic risk score (PRS313) may help predict future breast cancer in pts with DCIS or LCIS, from Jasmine Timbres @kingscollegelondon.bsky.social

Higher PRS313 linked to higher contralateral risk (DCIS; HR = 1.3) & ipsilateral risk (LCIS; HR = 2.16)

ascopost.com/news/october...
October 15, 2025 at 4:27 PM
ascopost.bsky.social
In older adults with early-stage cervical cancer, adherence to recommended surgery or radiation significantly improved survival.

In @jamanetworkopen.com, Suk et al urge addressing barriers to adherence to reduce mortality in aging populations.

ascopost.com/news/october...
October 14, 2025 at 3:24 PM
ascopost.bsky.social
Study of 9/11 WTC first responders shows risks of toxic particulates from environmental catastrophes:
6× higher leukemia risk in responders with clonal hematopoiesis

But, targeting IL1RAP could reduce inflammation-driven disorders

ascopost.com/news/october...
9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers
“Our findings provide new insights into the long-term health impacts of environmental catastrophes, such as wildfires, and suggest targeted interventions for those affected by 9/11 or similar disaster...
ascopost.com
October 13, 2025 at 3:15 PM
ascopost.bsky.social
The @usfda.bsky.social has approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma

FDA approval based on findings from the C-POST study:
Median DFS not reached vs 49.4 months w/ placebo (HR = 0.32; P < .0001)

ascopost.com/news/october...
PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC
The FDA has approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation therapy.
ascopost.com
October 10, 2025 at 8:12 PM
ascopost.bsky.social
Patients with HER2+ mCRC receiving chemo + bevacizumab/anti-EGFR therapy face worse survival than pts with HER2– disease
- HR for PFS = 1.31 (P = .02)
- HR for OS = 1.37 (P = .01)

Corresponding author: Chiara Cremolini, MD, PhD

ascopost.com/news/october...
Impact of HER2-Receptor Status in mCRC Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs
In an analysis reported in the Journal of Clinical Oncology, Germani et al identified the impact of HER2 status in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy plus either ...
ascopost.com
October 9, 2025 at 7:20 PM
ascopost.bsky.social
Cases of kidney cancer projected to double by 2050 globally due to modifiable risk factors.
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...
Kidney Cancer Cases Expected to Double by 2050
A recent review tracked and projected the future global epidemiology of kidney cancer, examining its incidence, mortality, survival, genetic predisposition, and risk factors.
ascopost.com
October 8, 2025 at 5:16 PM
ascopost.bsky.social
BART Trial Presented at the ASTRO Annual Meeting: Adjuvant RT after cystectomy + chemo in MIBC improves survival with no excess grade ≥3 toxicity

One of the first large randomized trials to show meaningful pelvic relapse reductions, says Vedang Murthy, MD

ascopost.com/news/septemb...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy after radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from ...
ascopost.com
October 7, 2025 at 3:19 PM